DE69829880T2 - Konjugate enthaltend zwei wirkstoffe - Google Patents
Konjugate enthaltend zwei wirkstoffe Download PDFInfo
- Publication number
- DE69829880T2 DE69829880T2 DE69829880T DE69829880T DE69829880T2 DE 69829880 T2 DE69829880 T2 DE 69829880T2 DE 69829880 T DE69829880 T DE 69829880T DE 69829880 T DE69829880 T DE 69829880T DE 69829880 T2 DE69829880 T2 DE 69829880T2
- Authority
- DE
- Germany
- Prior art keywords
- fibrinogen
- agent
- conjugate according
- linker
- microcapsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 10
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 56
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 56
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 56
- 239000003094 microcapsule Substances 0.000 claims abstract description 38
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 34
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 34
- 229960000301 factor viii Drugs 0.000 claims abstract description 33
- 125000000524 functional group Chemical group 0.000 claims abstract description 11
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 23
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 6
- 208000031220 Hemophilia Diseases 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 238000010382 chemical cross-linking Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 abstract description 5
- 108010088751 Albumins Proteins 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 125000006850 spacer group Chemical group 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 125000003396 thiol group Chemical group [H]S* 0.000 description 13
- 125000005647 linker group Chemical group 0.000 description 11
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000001588 bifunctional effect Effects 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 150000007857 hydrazones Chemical class 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
- NITXODYAMWZEJY-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanehydrazide Chemical compound NNC(=O)CCSSC1=CC=CC=N1 NITXODYAMWZEJY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- -1 Sulfo-NHS ester Chemical class 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000006855 networking Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- VYMHBQQZUYHXSS-UHFFFAOYSA-N 2-(3h-dithiol-3-yl)pyridine Chemical group C1=CSSC1C1=CC=CC=N1 VYMHBQQZUYHXSS-UHFFFAOYSA-N 0.000 description 1
- DSYBJJPCWALMGQ-UHFFFAOYSA-N 3-(iminomethylideneamino)-1-n,1-n'-dimethylpentane-1,1-diamine Chemical compound N=C=NC(CC)CC(NC)NC DSYBJJPCWALMGQ-UHFFFAOYSA-N 0.000 description 1
- XCXDQEVVSKEOIO-UHFFFAOYSA-N 3-(iminomethylideneamino)-1-n,3-n-dimethylpentane-1,3-diamine Chemical compound N=C=NC(CC)(NC)CCNC XCXDQEVVSKEOIO-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 229920001744 Polyaldehyde Polymers 0.000 description 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940002246 alphanate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 108010033683 von Willebrand factor drug combination factor VIII Proteins 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Detergent Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9724143.4A GB9724143D0 (en) | 1997-11-14 | 1997-11-14 | Pharmaceutical conjugate |
| GB9724143 | 1997-11-14 | ||
| PCT/GB1998/003442 WO1999025383A1 (en) | 1997-11-14 | 1998-11-16 | Conjugates comprising two active agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69829880D1 DE69829880D1 (de) | 2005-05-25 |
| DE69829880T2 true DE69829880T2 (de) | 2005-09-22 |
Family
ID=10822123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69829880T Expired - Lifetime DE69829880T2 (de) | 1997-11-14 | 1998-11-16 | Konjugate enthaltend zwei wirkstoffe |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7001989B2 (https=) |
| EP (1) | EP1047452B1 (https=) |
| JP (1) | JP2001523648A (https=) |
| AT (1) | ATE293459T1 (https=) |
| AU (1) | AU1165899A (https=) |
| DE (1) | DE69829880T2 (https=) |
| ES (1) | ES2238774T3 (https=) |
| GB (1) | GB9724143D0 (https=) |
| WO (1) | WO1999025383A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6933366B2 (en) * | 1996-12-27 | 2005-08-23 | Tripep Ab | Specificity exchangers that redirect antibodies to bacterial adhesion receptors |
| WO1999064072A1 (de) * | 1998-06-10 | 1999-12-16 | Baxter Aktiengesellschaft | Konjugat, bestehend aus einem lektin und einem blutgerinnungsfaktor |
| GB9825105D0 (en) * | 1998-11-16 | 1999-01-13 | Andaris Ltd | Pharamaceutical conjugates |
| GB9827813D0 (en) * | 1998-12-17 | 1999-02-10 | Andaris Ltd | Pharmaceutical conjugates |
| DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| AU6389000A (en) * | 1999-07-28 | 2001-02-19 | Valentis, Inc. | Sonoporation of tumors |
| GB0323378D0 (en) * | 2003-10-07 | 2003-11-05 | Univ Leicester | Therapeutic agent |
| JP5230610B2 (ja) | 2006-05-05 | 2013-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 二価ｓｍａｃ模倣物およびその使用 |
| GB0623607D0 (en) * | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
| US20090170195A1 (en) * | 2007-12-28 | 2009-07-02 | Kent State University | Curcumin-hyaluronan compounds |
| CN102112144A (zh) | 2008-05-16 | 2011-06-29 | 拜耳医药保健有限公司 | 靶向性凝固因子及其使用方法 |
| JP5770161B2 (ja) * | 2009-04-06 | 2015-08-26 | ノヴォ ノルディスク アー／エス | 血小板への第ｖｉｉｉ因子タンパク質の標的送達 |
| GB201101740D0 (en) * | 2011-02-01 | 2011-03-16 | Haemostatix Ltd | Therapeutic agents with improved fibrinogen binding |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| IL85372A (en) * | 1987-02-12 | 1992-12-01 | Us Health | Penta to nona-peptides with laminin - like activity having an amino acid sequence and anti- metastatic compositions containing them |
| WO1996039128A1 (en) | 1995-06-06 | 1996-12-12 | Hemosphere, Inc. | Protein particles for therapeutic and diagnostic use |
| US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
| PT796090E (pt) * | 1994-12-16 | 2003-07-31 | Elan Drug Delivery Ltd | Microparticulas reticuladas e sua utilizacao como veiculos terapeuticos |
| ES2232862T3 (es) * | 1996-10-21 | 2005-06-01 | Quadrant Drug Delivery Limited | Sustitutos de plaquetas y procedimientos de conjugacion apropiados para su preparacion. |
-
1997
- 1997-11-14 GB GBGB9724143.4A patent/GB9724143D0/en not_active Ceased
-
1998
- 1998-11-16 AU AU11658/99A patent/AU1165899A/en not_active Abandoned
- 1998-11-16 DE DE69829880T patent/DE69829880T2/de not_active Expired - Lifetime
- 1998-11-16 AT AT98954603T patent/ATE293459T1/de active
- 1998-11-16 WO PCT/GB1998/003442 patent/WO1999025383A1/en not_active Ceased
- 1998-11-16 ES ES98954603T patent/ES2238774T3/es not_active Expired - Lifetime
- 1998-11-16 JP JP2000520816A patent/JP2001523648A/ja active Pending
- 1998-11-16 EP EP98954603A patent/EP1047452B1/en not_active Expired - Lifetime
-
2002
- 2002-11-22 US US10/302,428 patent/US7001989B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU1165899A (en) | 1999-06-07 |
| JP2001523648A (ja) | 2001-11-27 |
| US7001989B2 (en) | 2006-02-21 |
| ES2238774T3 (es) | 2005-09-01 |
| WO1999025383A1 (en) | 1999-05-27 |
| GB9724143D0 (en) | 1998-01-14 |
| EP1047452B1 (en) | 2005-04-20 |
| EP1047452A1 (en) | 2000-11-02 |
| DE69829880D1 (de) | 2005-05-25 |
| US20030087826A1 (en) | 2003-05-08 |
| ATE293459T1 (de) | 2005-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69731985T2 (de) | Plättchen-ersatzmittel und geeignetes konjugations-herstellungsverfahren | |
| DE10121982B4 (de) | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung | |
| DE3889340T2 (de) | Verbreitung von arzneimittelsystemen. | |
| DE69529917T2 (de) | Vernetzte mikropartikel und ihre verwendung als arzneiträger | |
| DE3751574T2 (de) | Diagnose- und heilmittel-antikörperkonjugate. | |
| DE69829880T2 (de) | Konjugate enthaltend zwei wirkstoffe | |
| US5456922A (en) | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone | |
| DE69822473T2 (de) | Lipid-polyamid-konjugate und zusammensetzungen zur verabreichung von nucleinsäuremolekülen | |
| DE3382572T2 (de) | Antikoerper-verbindungen. | |
| DE69430450T2 (de) | Zell- und serum- proteinanker und konjugate | |
| EP0186616B1 (de) | Magnetische Partikel für die Diagnostik | |
| US5258499A (en) | Liposome targeting using receptor specific ligands | |
| EP2347770B2 (de) | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung | |
| DE69333929T2 (de) | Konjugate von alginat und bioaktiven mitteln | |
| DE69430251T2 (de) | Verbesserte interferon-polymerkonjugate | |
| DE69431185T2 (de) | Erweiterung des vitamin b 12 - aufnahmesystems unter verwendung von polymeren | |
| DE3853792T2 (de) | Amin-Derivate von Anthracyclin-Antibiotika. | |
| DE3885317T2 (de) | Makromolekulare Platin-Antitumorverbindungen. | |
| KR890004687B1 (ko) | 생물학적 활성 서방출성 조성물 | |
| DE69708304T2 (de) | Vernetzte copolymere auf der basis von polycarbonsäurepolymeren | |
| DE69928472T2 (de) | Stabilisierte pharmazeutische Zusammensetzungen von Hedgehog-Proteinen und deren Verwendung | |
| DE69232006T2 (de) | Pharmazeutische zusammensetzungen | |
| DD297842A5 (de) | Neue protein-polykation-konjugate | |
| EP1993609A2 (de) | Wirkstoffbeladene nanopartikel auf basis hydrophiler proteine | |
| DE69019959T2 (de) | Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |